ClinicalTrials.gg
RecruitingNCT04817072EMOTIONUpdated Jul 9, 2025

Evaluation of Mood Disorders Under Biologics in Chronic Inflammatory Rheumatic Disease

An interventional study of Blood sample in Rheumatic Diseases and Mood Disorders, sponsored by Centre Hospitalier Universitaire de Besancon. Recruiting at 1 site in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-07-09.

Sponsored by Centre Hospitalier Universitaire de Besancon · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started May 2021; still recruiting 5 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
108
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Rheumatic Diseases with a site in France — 8 open to participants now, 8 under way, none of them phase 3. Rheumatic Diseases · France.

Planned enrollment
6th of 10
108 · median 123
Started
2021
with 2 others
No phase
8 of 25
3 open now
Registered
18th of 25
by date
Lead sponsor
1 of 25
Centre Hospitalier Universitaire de Besancon

Among the 25 studies in Rheumatic Diseases with a site in France, this one is the 6th largest by planned enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2021, is one of 8 with no phase, and was the 18th registered.

Rheumatic Diseases

264 studies on the registry are indexed under Rheumatic Diseases; 60 are open to participants now.

Browse Rheumatic Diseases studies →

Open to participants now

8 of the 25 studies in Rheumatic Diseases with a site in France are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 41 Rheumatic Diseases studies recruiting now, 18 (44%) set no upper age limit and 12 (29%) stop at 75 or younger; 7 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Rheumatic Diseases with a site in France, or all of them as a file.
02

Study summary

Chronic inflammatory rheumatic diseases (CIRD) affect many organ systems. Painful sensations within the joints spine, hand and foot deformities, low quality of life and psychosocial status in patients with rheumatoid arthritis, spondyloarthritis and psoriatic arthritis can lead to the development of anxiety and depression. Prevalences of anxiety increase in patients suffering of CIRD, compared with healthy individuals. Another connection has been identified by the links between depression and systemic inflammation. It is proven that higher plasma levels of pro-inflammatory cytokines such as tumor necrosis factor alpha (TNFa) affect neurotransmitter metabolism, with influence on patients mood. The purpose of EMOTION study is therefore to analyze thymic variation under TNFa therapy, as treatment of CIRDs.

03

Conditions studied

  • Rheumatic Diseases
  • Mood Disorders

Keywords

  • TNF alpha inhibitor
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (≥18 ; ≤ 80)
  • Patient with rheumatoid arthritis (RA) according to the ACR 2010 criteria, axial or peripheral spondyloarthritis (SpA) according to ASAS criteria, ankylosing spondylitis (AS) according to the New York criteria or psoriatic arthritis (PsA) according to CASPAR criteria
  • Signature of
  • Affiliation to a French social security or receiving such a scheme

Exclusion criteria

Exclusion Criteria:

  • Patient having previously received anti-TNFα treatment
  • Patient with previously diagnosed depressive or psychiatric pathology and / or receiving anti-depressant treatment
  • Subjects with limited legal capacity.
  • Subjects judged by the investigator to be unlikely to comply with study procedures
  • Subjects with no social security coverage.
  • Pregnant women.
  • Subjects still in the exclusion period of another study, or according to the national registry of clinical trial participants.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
108 participants (estimated)

Study arms

  • Other
    Chronic inflammatory rheumatic disease

    Patients presenting a chronic inflammatory rheumatic disease (rheumatoid arthritis, spondyloarthritis or psoriatic arthritis), requiring anti-TNFa therapy and with a QIDS SR-16 (QIDS-SR 16-Quick Inventory of Depressive Symptomatology-Self Reported 16 items) score between 6 and 19

    Other: Blood sample

Interventions

  • OtherBlood sample

    Blood sample (20mL) for pro-inflammatory cytokines assay

06

What researchers measure

Primary outcomes

  1. Severity of depressive symptoms

    Score achieved on the validated self-report questionnaire (QIDS SR16) evaluating the severity of depressive symptoms

    Time frame: 1 month after initiation of anti-TNFa therapy

Secondary outcomes

  1. Evaluation of disease activity

    Evaluation with CPDAI (Composite Psoriatic Disease Activity Index) (minimum value: 0; maximum value: 15; increases with the activity of the disease)

    Time frame: 3 months after initiation of anti-TNFa therapy

  2. Evaluation of disease activity

    Evaluation with DAS28 (Disease Activity Score 28-joint count) (minimum value: 0; maximum value: 9.4; increases with the activity of the disease)

    Time frame: 3 months after initiation of anti-TNFa therapy

  3. Evaluation of disease activity

    Evaluation with BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) (minimum value: 0 (no disease activity); maximum value: 10 (very active disease))

    Time frame: 3 months after initiation of anti-TNFa therapy

  4. Evaluation of disease activity

    Evaluation with ASDAS (Ankylosing Spondylitis Disease Activity Score) (minimum value: 0 (no disease activity); value \>3.5 between : very high disease activity)

    Time frame: 3 months after initiation of anti-TNFa therapy

  5. Evaluation of Fatigue

    Evaluation with Functional Assessment of Chronic Illness Therapy

    Time frame: 3 months after initiation of anti-TNFa therapy

  6. Evaluation of Pleasure

    Evaluation with Snaith-Hamilton pleasure scale (minimum value: 0 (no disease activity); maximum value: 14 (very active disease)). A higher total SHAPS score indicated higher levels of anhedonia.

    Time frame: 3 months after initiation of anti-TNFa therapy

07

Study locations

1 of 1 sites recruiting
  • University Hospital
    Besançon, 25000, France
    Recruiting
    • Charline VAUCHY · Contact
    • Eric Toussirot, PU-PH · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2021 (actual). Primary completion is estimated for Nov 2025, 54 months after the start.

Of 72 non-industry interventional studies with no phase under Rheumatic Diseases, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 54 months is above that.

Counting every sponsor, half of 74 studies reached it within 26 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2021
First posted
Mar 25, 2021
StartActual
May 19, 2021
Primary completionEst.
Nov 2025
CompletionEst.
May 2026
Last update
Jul 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04817072
Responsible party
Sponsor
First posted
Mar 25, 2021
Start date
May 19, 2021
Primary completion
Nov 2025 (estimated)
Completion
May 2026 (estimated)
Last update
Jul 9, 2025

Study contacts

Charline Vauchy, PhD
Contact
cvauchy@chu-besancon.fr
+333 81 21 88 75
Magali Nicolier-Pallandre, PhD
Contact
Eric Toussirot, PU-PH
principal investigator · Besançon University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion